@RightBioMetrics honored as finalist for a Global Patient Safety Innovation Award -

Check out what is happening in the science and entrepreneurial community this month!.

Join millions who have switched to Grok.

According to research, the primary reason cited by investors for lack of funding is "excessive risk." The reality is that many early-stage investors simply lack the technical expertise needed to evaluate risk, and, therefore, most regions under-invest in early stage companies.

BioAccel’s portfolio to date has resulted in a current book value of the portfolio that exceeds $98.3M with a projected exit value of $1.4B, achieving a 37 percent internal rate of return (IRR).

Check out the article:

One of our portfolio partners, LIfe365, added two new board of advisor members. We are pleased to welcome Ron Diamond and Jay H. Sanders to Life365 and we are excited to see the progress they will make!.

While BioAccel uses philanthropic funding to bridge the Valley of Death stage of business development unique to bioscience innovation, our novel nonprofit status also allows the holding of equity in exchange for early-stage investments, which ensures our long-term sustainability.

This work is critically important for U.S. competitiveness because if the U.S.were able to commercialize only 6 percent more federally funded research discoveries, the result would be a $1.4 trillion to $3 trillion impact on the national Gross Domestic Product.

Based in metropolitan Phoenix, Arizona, BioAccel accelerates the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support.

BioAccel is the only 501(c)3 organization in the Southwestern United States that fulfills a mission to drive economic development through accelerating commercialization of bioscience technology with a unique combination of early funding and entrepreneur mentorship and training.

While BioAccel uses philanthropic funding to bridge the high-risk Valley of Death stage of business development unique to bioscience innovation, our novel nonprofit status also allows the holding of equity in exchange for early-stage investments, which ensures our sustainability.

Where 33 other states had deployed seed capital funds by 2013, Arizona has none. The need to establish multiple early-stage funds and ensure their participants and beneficiaries extend beyond personal investment silos has never been greater.

BioAccel is a 501(c)3 non-profit organization that creates vibrant communities by transforming discoveries into new companies. We achieve this through our three strategic priorities: diversified economic growth, improved health, and entrepreneurial education and outreach.

Research conducted by Battelle showed that from 2002 to 2011, while the U.S. posted a 12 percent gain in bioscience jobs, Arizona’s bioscience jobs grew 45 percent -- more than 30,700 jobs, to reach a total of 99,018 bioscience jobs during that time period.

Our insight is based on a formal evaluation program that includes pre- and post-program assessments completed by our management team and reviewed by our independent BioAccel Council of Advisors.

While BioAccel uses philanthropic funding to bridge the Valley of Death stage of business development unique to bioscience innovation, our novel nonprofit status also allows the holding of equity in exchange for early-stage investments, which ensures our long-term sustainability.

Founded in 2009 by MaryAnn Guerra and Ron King, BioAccel provides training, investor education and a competitive early-stage funding for qualified innovators focused on health informatics and medical devices.

BioAccel’s work is critically important for U.S. competitiveness. According to The Kauffman Foundation’s research, the ability for U.S. firms to commercialize only 6 percent more federally funded research discoveries would result in a $1.4 trillion to $3 trillion impact.

While BioAccel uses philanthropic funding to bridge the Valley of Death stage of business development unique to bioscience innovation, our novel nonprofit status also allows the holding of equity in exchange for early-stage investments, which ensures our long-term sustainability.

Check out this article including our partner @Stimwave and the impact the stimulator market is having on healthcare.

We are proud to announce that our portfolio partner, @Stimwave, announced that legendary pioneer in pain management Andrea M. Trescot, MD, FIPP as its chief medical officer. We know they will accomplish amazing things especially under this new leadership!.